Phase-3 Data-sets for ABBV/ENTA includes statistically meaningful clinical data for HCV pts with cirrhosis. GILD dose not have such data. Consequently, ABBV/ENTA can market their HCV drug specifically to pts with cirrhosis. GILD does not have such luxury.